Thinking and memory after radiosurgery for several brain metastases
Studies thinking abilities in adults with multiple brain metastases receiving focused radiation treatment.
Key facts
- Who runs it
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Where
- Philadelphia and Sewell, United StatesSee the 2 sites
- Trial code
- Registry title
- Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
- Status
- Recruiting
- People taking part
- 90 people, planned
- Started
- 21 Feb 2017
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Cognitive Assessment
- Stereotactic Radiosurgery
- Stereotactic Body Radiation Therapy
- Quality-of-Life Assessment
- Record updated
- 16 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with 1 to 10 brain metastases from a solid tumor. They will have focused radiation (SRS or SBRT) and memory and thinking tests.
- Age
- 18 Years and older
- Sex
- All sexes can join
- Disease stage
- 1 to 10 brain metastases from a solid tumor proven by tissue testing. No more than two lesions or cavities of 3 cm (1.2 in) or more. The largest lesion or cavity is at most 6 cm (2.4 in). Karnofsky performance status of 60 or more.
- Earlier treatment
- Cannot have had brain surgery within 14 days before enrollment. Cannot have chemotherapy planned during radiosurgery.
- Biomarker or test result
- Serum creatinine =< 3 mg/dL (265 µmol/L) and creatinine clearance >= 30 ml/min. Women who can become pregnant need a negative pregnancy test within 21 days before registration.
Main reasons for not taking part
- Small cell lung cancer or germ cell tumor
- Glioma or another WHO grade II - IV primary brain tumor
- Cancer spread to the lining of the brain (leptomeningeal metastases)
- Seizures not controlled by medicine: more than 1 per week for the past 2 months
- Pregnant women
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Pathologically proven solid tumor malignancy (except for small cell lung cancer [SCLC], germ cell tumor)
- Karnofsky performance status >= 60
- 1 to 10 brain metastases (mets) (no more than two lesions and/or cavities >= 3 cm in maximum diameter)
- Maximum diameter of brain metastasis or resection cavity is 6 cm
- Serum creatinine =< 3 mg/dL and creatinine clearance >= 30 ml/min
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up; patients must be willing to complete neurocognitive assessments at pre-specified time points outlined in the protocol
- Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 21 days prior to registration
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose
- Patient able to provide his/her own written informed consent and speak English
Who cannot take part
- Prior brain surgery =< 14 days prior to enrollment
- Planned chemotherapy during radiosurgery
- Intractable seizures while on adequate anticonvulsant therapy-more than 1 seizure per week for the past 2 months
- Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor
- Leptomeningeal metastases
- Pregnant women
Where in United States
- Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhiladelphia, United StatesContact: Wenyin Shi, MDTaking people
- Jefferson Health New JerseySewell, United StatesContact: Karishma Kurowski, MPHNot yet recruiting
About the trial
What the trial wants to find out
This phase II trial studies the neurological function in patients with multiple brain metastases undergoing stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Assessment of neurocognitive function may help show that SRS preserves neurological function in patients with multiple brain metastases better than SBRT.
The group in the trial
- Supportive care (SRS/SBRT, neurocognitive testing)Treatment being tested
Patients undergo SRS on day 1 or SBRT for 3 fractions over days 1-7 and undergo neurocognitive testing at baseline, 4, and 12 months after undergoing SRS or SBRT.
Treatment: Cognitive Assessment, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy, and Quality-of-Life Assessment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study
- Plain-language title
- Thinking and memory after radiosurgery for several brain metastasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 16 November 2026